Prazosin: No new patients and discontinuation

Discontinuation Access change Active

Prazosin is being discontinued and prazosin will only be funded for existing patients from 1 August 2021.

Why are we doing this?

All strengths of prazosin (1 mg, 2 mg and 5 mg) are currently supplied by Apotex. Apotex is leaving the New Zealand market. We have been looking for new suppliers for all the medicines they currently supply. 

We have been unable to find an alternative supplier for prazosin. 

We are making these changes so current patients can access prazosin for as long as possible.

Key dates 

1 August 2021: No new patients

  • Funding will be restricted to people who were using prazosin before 1 August 2021. 
  • Pharmacists can endorse the script where they have a record of a previous dispensing of prazosin.

1 May 2022: Prazosin delisted

  • We anticipate that stocks of prazosin will be exhausted before the end of the year. 
  • The May delisting date allows all stock in the supply chain to be used up.  

Alternative product 

We have received clinical advice that doxazosin may be a suitable alternative for people to be transitioned to. 

Doxazosin monograph | NZ Formulary(external link)

Doxazosin listing | Pharmaceutical Schedule(external link)

We are aware that prazosin is being prescribed off-label for the management of symptoms relating to PTSD. Please contact local psychiatry services to seek advice on alternative treatments people may be transitioned to.

Who to contact 

If you are taking prazosin, talk to your pharmacist or the person who prescribed the prazosin. They are in the best place to advise on your clinical circumstances. 

If you have funding questions about prazosin, email

Pharmac's response to Apotex's departure